The aim of this study was to examine whether non-high-density lipoprotein cholesterol (non-HDL-cholesterol) raises the risk of coronary heart disease in a dose-response fashion in a non-obese population with low total cholesterol levels and high HDL-cholesterol levels, such as Japanese. Methods: A total of 30,802 men and 60,417 women, aged 40 to 79 years with no history of stroke or coronary heart disease, completed a baseline risk factor survey in 1993 under the auspices of the Ibaraki Prefectural Health Study. Systematic mortality surveillance through 2003 identified 539 coronary heart disease deaths.
Introduction
Non-high-density lipoprotein cholesterol (non-HDL-cholesterol) is one of the major atherogenic lipoproteins and has been identified by the National Cholesterol Educational Program (NCEP) Expert Panel as one of the secondary targets for the prevention of coronary heart disease 1, 2) . recent prospective cohort study of 4,694 urban Japanese observed a positive association between non-HDL-cholesterol and the risk of myocardial infarction 10) ; however, it showed a non-linear association for men and no association for women, possibly due to the small number of myocardial infarction cases.
To examine whether non-HDL-cholesterol raises the risk of coronary heart disease mortality in current Japanese rural populations, we conducted a large cohort study of approximately 91,000 Japanese men and women.
Methods

Study Cohort and Population
In 1993, the Ibaraki Prefectural government initiated a community-based cohort study, known as the Ibaraki Prefectural Health Study, to obtain information on health status for the purpose of health education and policy making 14) . The participants in the cohort were 98,196 individuals (33,414 men and 64,782 women) aged 40 − 79 years, living in Ibaraki Prefecture, who underwent an annual health check-up in 1993, which included the examination of blood lipids for 96,610 individuals (32,984 men and 63,626 women).
We excluded 5,391 individuals (2,182 men and 3,209 women) from our analysis because of a previous history of stroke and coronary heart disease at the time of baseline inquiry. Thus, 91,219 individuals (30,802 men and 60,417 women) were enrolled in the study presented here.
Informed consent was obtained from the community representatives to conduct an epidemiological study based on the guidelines of the Council for International Organizations of Medical Science 15) . The Ethics Committee of Ibaraki Prefecture approved this study.
Measurement of Risk Factors
Serum total cholesterol and triglycerides were measured with enzymatic methods using an RX-30 device (Nihon Denshi, Tokyo, Japan) and high-density lipoprotein cholesterol (HDL-cholesterol) levels were measured with phosphotungstic acid-magnesium methods using an MTP-32 (Corona Electric, Ibaraki, Japan). These measurements were performed on the premises of the Ibaraki Health Service Association, and were standardized by the Osaka Medical Center for Health Science and Promotion under the aegis of the US National Cholesterol Reference Method Laboratory Network (CRMLN). The laboratory of the Osaka Medical Center for Health Science and Promotion has been standardized since 1975 by the CDC-NHLBI Lipid Standardization Program provided by the Center for Disease Control and Prevention (Atlanta, GA) and has met all the criteria for both precision and accuracy of lipid measurements 16) . Non-HDL-cholesterol was calculated as follows: non-HDLcholesterol (mg/dL) total cholesterol (mg/dL) HDLcholesterol (mg/dL).
Mild hypertension was defined as systolic blood pressure 140 − 159 mmHg or diastolic blood pressure 90 − 99 mmHg, and the corresponding values were 160 − 179 mmHg or 100 − 109 mmHg for moderate hypertension and ≥ 180 mmHg or ≥ 110 mmHg for severe hypertension. Diabetes was defined as a plasma glucose level of ≥ 126 mg/dL ( ≥ 7.0 mmol/L) during fasting or ≥ 200 mg/dL ( ≥ 11.1 mmol/L) during nonfasting, or the use of medication for diabetes, and impaired glucose tolerance was defined as a plasma glucose level of 110 − 125 mg/dL (6.1 − 6.9 mmol/L) at fasting or 140 − 199 mg/dL (7.8 − 11.0 mmol/L) at nonfasting, and no use of medication for diabetes. Kidney dysfunction was defined as a serum creatinine level of ≥ 1.2 mg/dL ( ≥ 110 mol/L) for men or ≥ 1.0 mg/dL ( ≥ 90 mol/L) for women, and/or a history of kidney disease. Height in stocking feet and weight in light clothing were measured, and body mass index (BMI) was calculated as weight (kg)/height (m) 2 . An interview was conducted to ascertain smoking status, the number of cigarettes smoked per day, usual weekly intake of alcohol in go units (a Japanese traditional unit of alcohol intake converted to grams of ethanol per day at 23 g ethanol per go unit), and histories of stroke and heart disease. Current drinkers were defined as occasional and habitual drinkers.
Follow-Up Surveillance
To ascertain deaths in the cohort, the investigators conducted a systematic review of death certificates, which in Japan are all forwarded to the local public health center of every community. It is believed that all deaths that occurred in the cohort were ascertained, except for subjects who died after they had moved from their original community, in which case the subject was treated as a censored case. Mortality data are centralized at the Ministry of Health and Welfare, where the underlying causes of death are coded for National Vital Statistics according to the International Classification of Disease, 9th (1993 − 1994) and 10th (1995 − 2004) revisions (410 − 414 for International Classification of Disease, 9th revision, and code I20 to I25 for 10th revision).
The follow-up inquiry for this study was conducted until the end of 2003, and the median fol-low-up was 10.3 years. Only 3.2% of the subjects had moved out of their respective communities, and were treated as censored.
Statistical Analysis
Statistical analysis was based on mortality rates from coronary heart disease divided by clinical categories of non-HDL-cholesterol ( 100, 100 − 120, 120 − 139, 140 − 159, 160 − 179, ≥ 180 mg/dL: 2.59, 2.59 − 3.09, 3.10 − 3.61, 3.62 − 4.13, 4.14 − 4.64, and ≥ 4.65 mmol/L). Person-years of follow-up were calculated from the date of the baseline survey to the date of death, exit from the community, or the end of 2003, whichever occurred first.
Sex-specific age-adjusted means and proportions of selected cardiovascular risk factors at baseline were determined in terms of the non-HDL-cholesterols categories. The t-test or chi-square test was used to examine differences in age-adjusted mean values and proportions of baseline characteristics from those of the lowest non-HDL-cholesterol category. Age-adjusted and multivariable hazard ratios (HR) and 95% confidence intervals (95%CI) were calculated with the Cox proportional hazards model after adjustment for age and potential confounding factors. These potential confounding factors included body mass index (sexspecific quintiles), blood pressure categories (normal, mild hypertension, moderate hypertension, or severe hypertension), anti-hypertensive medication use (yes or no) diabetes status (normal, impaired glucose tolerance, or diabetes), gamma-glutamyl transferase (sexspecific quintiles), kidney dysfunction (yes or no), smoking status (never, ex-smoker, or current smokers of 1 to 19 or ≥ 20 cigarettes per day), alcohol intake category (never, ex-drinkers, occasional drinkers and habitual drinkers consuming 69 g/day or ≥ 69 g/day of ethanol, respectively), HDL-cholesterol ( 40, 40 − 49, 50 − 59, 60 − 69, ≥ 70 mg/dL or 1.03, 1.03 − 1.28, 1.29 − 1.54, 1.55 − 1.80, ≥ 1.81 mmol/L) and triglycerides ( 100, 100 − 149, 150 − 199, 200 − 249, 250 − 299, ≥ 300 mg/dL or 1.12, 1.12 − 1.68, 1.69 − 2.24, 2.25 − 2.81, 2.82 − 3.37, ≥ 3.38 mmol/L). We tested the assumption of proportional hazards for non-HDLcholesterol categories 17) and found no violation of proportionality. Tests for effect modification by sex or other variables were conducted with an interaction term generated by multiplying the continuous variables of non-HDL-cholesterol by sex or other variables. We conducted an additional analysis after the exclusion of individvals with hypertriglyceridemia (triglycerides ≥ 802 mg/dL) at baseline survey (55 men and 23 women), and those using lipid-lowering medication at the baseline survey (370 men and 1,903 women). We also analyzed the data of the sub-population with fasting serum samples (within 8 hours after last meal) at the baseline survey (5,375 men and 10,268 women).
We further analyzed the Cox proportional hazard model with time-dependent covariates, using the additional data of non-HDL-cholesterol and confounding factors for 80,578 persons (88.3% of the participants) whose blood lipids had been examined more than twice. The median duration between the date of the latest examination and the date of the end of follow-up was 0.7 years.
All statistical tests were two-sided. SAS, version 9.13 (SAS Institute, Inc., Cary, NC, USA) was used for all statistical analyses.
Results
A total of 91,219 persons (30,802 men and 60,417 women) were followed up for a median of 10.3 years, during which time 295 men and 244 women died from coronary heart disease. The mean (standard deviation: SD) non-HDL-cholesterol level was 140.4 (35.3) mg/dL for men and 150.8 (35.6) mg/dL for women. The corresponding mean (SD) was 192.5 (33.9) mg/dL and 207.6 (34.8) mg/dL in total cholesterol and 52.3 (14.9) mg/dL and 56.7 (14.0) mg/ dL in HDL-cholesterol. The prevalence of obesity (BMI ≥ 30.0 kg/m 2 ) was 1.7% for men and 3.3% for women. Table 1 shows selected cardiovascular risk factors by non-HDL-cholesterol concentration category. Compared with men who had the lowest levels of non-HDL-cholesterol ( 100 mg/dL: 2.59 mmol/L), those who had the highest levels (≥ 180 mg/dL: ≥ 4.65 mnom/L) were younger, more likely to use medication for hypertension and lipid abnormality, and less likely to smoke currently or drink heavily. They also tended to have diabetes and kidney dysfunction, a higher mean of systolic and diastolic blood pressure, body mass index, total cholesterol levels and triglyceride levels, and a lower mean of HDL-cholesterol. Similar associations were observed for women, except for age and gamma-glutamyl transferase levels. Compared with women who had the lowest non-HDL-cholesterol levels, women with the highest levels were older and had higher gamma-glutamyl transferase levels.
Age-adjusted mortality from coronary heart disease was twice as high for the highest as for the lowest non-HDL-cholesterol category for men, while there was no such association for women ( Table 2) . Multivariable HR (95%CI) of coronary heart disease mortality for the highest versus lowest concentrations of Table 2 . Gender-specific age-adjusted and multivariable hazard ratio (HR) and 95% confidence interval (95%CI) of mortality from coronary heart disease and all-causes according to non-HDL-cholesterol levels On the other hand, higher levels of non-HDLcholesterol were associated with a reduced risk of allcause mortality for both men and women ( Table 2) . Multivariable HR (95%CI) of all-cause mortality for the highest versus lowest non-HDL-cholesterol levels was 0.64 (0.56 − 0.73), p 0.0001 for men, and 0.55 (0.47 − 0.66), p 0.0001 for women.
We observed no interaction of the fasting/ non-fasting status in the association between non-HDL-cholesterol and mortality from coronary heart disease ( Table 3) . When we stratified the data on the sub-population by fasting status, the associations did not differ substantially. No statistically significant interaction of the association between non-HDL-cholesterol and mortality from coronary heart disease was observed for other potential risk factors (p 0.20) except for gender difference, diabetes and gamma-glutamyl transferase (Table 3) . 
Discussion
In the large population-based prospective cohort study of Japanese reported here, we observed, in a less obese population, significant positive associations of high non-HDL-cholesterol with an increased risk of mortality from coronary heart disease for men, but not for women. These associations did not alter substantially after adjusting for potential confounding factors, and after excluding non-fasting subjects or those with hypertriglyceridemia, or using of timedependent covariates.
For this study population, the mean non-HDLcholesterol level was 140 mg/dL for men and 151 mg/dL for women at baseline. Previous studies involving participants with higher non-HDL-cholesterol levels: for example, the Framingham Heart study (mean non-HDL-cholesterol at baseline: 168 mg/dL for men and 160 mg/dL for women) 3) , the Health Professionals follow-up Study (158 mg/dL for men) 4) , Women's Health Study (155 mg/dL for women) 5, 6) , Lipid Research Clinical Program Follow-up Study (181 mg/dL for men and 172 mg/dL for women) 7) , the Chin-Shan Community Cardiovascular Cohort study (150 mg/dL) 8) , and a recent meta-analysis (170 mg/ dL) 9) showed the relationship between higher concentrations of non-HDL-cholesterol and an increased risk of coronary heart disease. Our findings thus extend the previous evidence to the lower ranges of non-HDL-cholesterol.
We observed a statistically significant association of non-HDL-cholesterol with mortality from coronary heart disease among men, but not women. The possible mechanisms of the gender difference interaction are as follows. First, men often have more atherosclerotic risk factors than women, such as higher blood pressure, higher glucose levels and higher smoking prevalence 18) , which may accelerate the atherogenic effect of non-HDL-cholesterol. Second, there may be a gender difference in the cumulative burden from non-HDL-cholesterol during atherosclerosis development due to lag time to an increase in non-HDL-cholesterol levels over the lifespan. Pre-menopausal women have lower total cholesterol levels than men of the same age group 19) , which may result in a lower cumulative burden of atherosclerosis development for women than for men.
A limitation of the current study is that we used fasting and non-fasting serums for lipid measurements; however, there was no change in the association between non-HDL-cholesterol and coronary heart disease after stratification of the fasting status. Second, we used mortality data based on death certificate diagnoses, not the incidence data; however, three-fourths of death certificate diagnoses of coronary heart disease have been found to be correctly diagnosed 20, 21) . The strength of the present study is that we used lipid measurement values standardized in a single laboratory, which in turn was standardized by the CDC-NHLBI Lipid Standardized Program 16) . This justifies our assumption that misclassification bias due to errors in lipid measurement had been adequately reduced, and that the resultant accuracy lipid measurements were comparable with the results of previous wellstandardized studies.
In conclusion, our large cohort study provides epidemiological evidence that, in a less obese population, higher concentrations of non-HDL-cholesterol are associated with an increased risk of coronary heart disease mortality for men, but not for women.
